A novel preventive strategy against HIV-1 infection: combinatorial use of inhibitors targeting the nucleocapsid and fusion proteins

References

• UNAIDS.Prevention gap report. Available at http://www.unaids.org/en/resources/documents/2016/prevention-gap (accessed on 11 July 2016).
   Google Scholar
• Abdool KQ, Abdool KS, Frohlich JAet al.Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329: 1168–1174.
   PubMed Web of Science ®Google Scholar
• McGowan I, Hoesley C, Cranston RDet al.A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). PLoS One 2013;8: e60147.
   PubMed Web of Science ®Google Scholar
• Dezzutti CS, Russo J, Wang Let al.Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation. PLoS One 2014;9: e102585.
   PubMed Web of Science ®Google Scholar
• Herrera C, Armanasco N, Garcia-Perez Jet al.Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates. AIDS 2016;30: 1015–1025.
   PubMed Web of Science ®Google Scholar
• Herrera C, Cranage M, McGowan Iet al.Colorectal microbicide design: triple combinations of reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants. AIDS 2011;25: 1971–1979.
   PubMed Web of Science ®Google Scholar
• Herrera C, Cranage M, McGowan Iet al.Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother 2009;53: 1797–1807.
   PubMed Web of Science ®Google Scholar
• Dobard CW, Taylor A, Sharma Set al.Protection against rectal chimeric simian/human immunodeficiency virus transmission in macaques by rectal-specific gel formulations of maraviroc and tenofovir. J Infect Dis 2015;212: 1988–1995.
   PubMed Web of Science ®Google Scholar
• Veazey RS, Klasse PJ, Schader SMet al.Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005;438: 99–102.
   PubMed Web of Science ®Google Scholar
• Hiruy H, Fuchs EJ, Marzinke MAet al.A phase 1 randomized, blinded comparison of the pharmacokinetics and colonic distribution of three candidate rectal microbicide formulations of tenofovir 1% gel with simulated unprotected sex (CHARM-02). AIDS Res Hum Retroviruses 2015;31: 1098–1108.
   PubMed Web of Science ®Google Scholar
• Mcgowan I, Cranston RD, Duffill Ket al.A phase 1 randomized, open label, rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of three formulations of tenofovir 1% gel (the CHARM-01 study). PLoS One 2015;10: e0125363.
   PubMed Web of Science ®Google Scholar
• Miller JL, Hara T, Durell SRet al.Specificity of acyl transfer from 2-mercaptobenzamide thioesters to the HIV-1 nucleocapsid protein. J Am Chem Soc 2007;129: 11067–11078.
   PubMed Web of Science ®Google Scholar
• Srivastava P, Schito M, Fattah RJet al.Optimization of unique, uncharged thioesters as inhibitors of HIV replication. Bioorg Med Chem 2004;12: 6437–6450.
   PubMed Web of Science ®Google Scholar
• Miller JL, Ott DE, Hayashi Ret al.Small-molecule inactivation of HIV-1 NCp7 by repetitive intracellular acyl transfer. Nat Chem Biol 2010;6: 887–889.
   PubMed Web of Science ®Google Scholar
• Denton PW, Othieno F, Martinez-Torres Fet al.One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J Virol 2011;85: 7582–7593.
   PubMed Web of Science ®Google Scholar
• He Y, Xiao Y, Song Het al.Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2008;283: 11126–11134.
   PubMed Web of Science ®Google Scholar
• Li L, Ben Y, Yuan S, Jiang S, Xu J, Zhang X.Efficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1. PLoS One 2012;7: e37381.
   PubMed Web of Science ®Google Scholar
• Wang RR, Yang LM, Wang YHet al.Sifuvirtide, a potent HIV fusion inhibitor peptide. Biochem Biophys Res Commun 2009;382: 540–544.
   PubMed Web of Science ®Google Scholar
• Ren Y, Li L, Wan Yet al.Mucosal topical microbicide candidates exert influence on the subsequent SIV infection and survival by regulating SIV-specific T-cell immune responses. J Acquir Immune Defic Syndr 2016;71: 121–129.
   PubMed Web of Science ®Google Scholar
• Bahde RJ, Appella DH, Trenkle WC.A one-pot preparation of N-2-mercaptobenzoyl-amino amides. Tetrahedron Lett 2011;52: 4103–4105.
   PubMed Web of Science ®Google Scholar
• Denizot F, Lang R.Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89: 271–277.
   PubMed Web of Science ®Google Scholar
• Yuan R, Cheng H, Chen LSet al.Prevalence of different HIV-1 subtypes in sexual transmission in China: a systematic review and meta-analysis. Epidemiol Infect 2016;144: 2144–2153.
   PubMed Web of Science ®Google Scholar
• Liu A, Yang Y, Liu Let al.Differential compartmentalization of HIV-targeting immune cells in inner and outer foreskin tissue. PLoS One 2014;9: e85176.
   PubMed Web of Science ®Google Scholar
• Qiu C, Peng H, Huang Xet al.Characterization of a new pseudotyped HIV with a single-round infectivity carrying enhanced green fluorescent protein gene. Chin J Microbiol Immunol 2006;26: 394–398.
   Google Scholar
• Li L, Ben Y, Zhu Zet al.Minocycline down-regulates topical mucosal inflammation during the application of microbicide candidates. PLoS One 2012;7: e43211.
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu AP, Meng QLet al. (Establishment of human colorectal tissue model in HIV-1 mucosal infection. Zhonghua Yu Fang Yi Xue Za Zhi 2011;45: 127–131.
   PubMedGoogle Scholar
• Fletcher PS, Elliott J, Grivel JCet al.Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 2006;20: 1237–1245.
   PubMed Web of Science ®Google Scholar
• Wallace GS, Cheng-Mayer C, Schito MLet al.Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection. J Virol 2009;83: 9175–9182.
   PubMed Web of Science ®Google Scholar
• Chou TC.Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58: 621–681.
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P.Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22: 27–55.
   PubMedGoogle Scholar
• Chou TC.The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. Am J Cancer Res 2011;1: 925–954.
   PubMed Web of Science ®Google Scholar
• Yao X, Chong H, Zhang Cet al.Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide. J Biol Chem 2012;287: 6788–6796.
   PubMed Web of Science ®Google Scholar
• Meng G, Sellers MT, Mosteller-Barnum Met al.Lamina propria lymphocytes, not macrophages, express CCR5 and CXCR4 and are the likely target cell for human immunodeficiency virus type 1 in the intestinal mucosa. J Infect Dis 2000;182: 785–791.
   PubMed Web of Science ®Google Scholar
• Li H, Bar KJ, Wang Set al.High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog 2010;6: e1000890.
   PubMed Web of Science ®Google Scholar